Fax: 613-947-3067
Email: ghi.info@nrc.gc.ca
100 Sussex Drive
Ottawa,
Ontario,
K1A 0R6
Canada

The potential of new human pathogen detection technologies is far reaching. Using a variety of technologies established in NRC-GHI Phase 3 this program aims to develop new tools for understanding the molecular processes underlying critical pathogenic and genetic diseases. The end goal is to create rapid point-of-care diagnostic devices with the capacity to improve both the speed and accuracy of patient treatment. In particular, research will focus on diagnosing infectious agents responsible for hospital-acquired infections and threats to food and water safety - leading issues that affect both the national health-care system and the well-being and health of Canadians.
Research SuccessDeveloping integrated devices that provide rapid point-of-care diagnosis of pathogens based on their genomic signature, is the goal of the NRC-GHI Biochips project. Central to the success of this technology are small on-chip assays – devices that can quantify, analyze and detect the chemical or molecular compounds found in various pathogens with high sensitivity and specificity. These small and efficient devices would assist in providing a sound “on-the-spot” clinical diagnosis and aide in determining the appropriate treatment, thereby preventing the spread of a variety of human disease. |